

## **President & CEO**

**Hiroshi Tomiyama, Ph.D.**

### **Qualifications**

1997: Ph.D. in Pharmaceutical Science

1992: Bachelor of Science in Pharmacy, Pharmacist

1990: Radiation Protection Officer

### **Work Experiences**

2017-2019: Part-time Lecturer (Concurrent)

Graduate School & Faculty of Pharmaceutical Sciences, Chiba University, Japan

Lecture content: "A Medicinal Chemist's Toolbox"

Training to identify metabolic sites of molecules at a glance;

Differences between theoretical organic reaction mechanisms and in reality.

2014 -present: President & CEO

2007: Executive Director

2002: Director, Product Planning & Coordination

2000: Joined with Kotobuki Pharma

1997-1999: Postdoctoral Researcher,

under the supervision of Professor Robert J. Linhardt, Division of Medicinal and Natural Products Chemistry (MNPC), College of Pharmacy, The University of Iowa, USA

Research subject; The synthesis of catabolically stable C-glycoside analogue of cancer carbohydrate antigen toward cancer vaccine development.

### **Awards**

#### **Medicinal Chemistry (Med. Chem.);**

2015: Breakthrough Award, Division of Medicinal Chemistry, Pharmaceutical Society of Japan

Title: Discovery of ipragliflozin (Suglat®): A potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus

#### **Pharmaceutical Engineering (Pharm. Eng.);**

2022: The 21st Century research grants, Nagano Pharmaceutical Association

Title: The development of easy to split with fingers and easy to swallow of "KAWARA" Orally Disintegrating tablets ®

### **Publications**

ScholarGPS® ID: 78182769548147